Yaben Chemical's Shangyu base will produce 'anti-aging drugs'
On July 17, an investor asked Yaben Chemical whether it was true that the company had completed the relevant procedures for nmn.
Yaben Chemical responded that the NMN project is one of the company's Shangyu base enzyme preparation and API projects. Currently, the Shangyu base is under construction, and the company will disclose relevant information in accordance with laws and regulations.
NMN is called β-nicotinamide mononucleotide, which is the precursor of NAD+ (coenzyme I) synthesis in the human body. Since NAD+ is a coenzyme for hundreds of important metabolic enzymes in cells, and as a signal molecule participates in many important cellular processes, it is closely related to energy metabolism, glycolysis, DNA replication and other activities, and NMN can increase the level of NAD+ in the body, which is considered It is a kind of health care product with anti-aging function, and some people simply call it "the elixir of life."
In the TOP10 list of 618 nutrition and health products third-party stores disclosed by JD.com, the first, second, sixth, and seventh places are all NMN-related health products. The emergence of NMN has caused the market. Restless, affected by this news, Yaben Chemical, as a concept stock, went out of 2 daily limits in 4 days.
Yaben Chemical is one of the few A-share listed companies that announced that they have NMN production technology. The company disclosed on October 11, 2019 that it plans to invest 450 million yuan in enzyme preparations and green research institute projects to develop and produce bio-enzyme preparations such as NMN and related biotech products.
According to the data, Yaben Chemical's main business is the research and development, production and sales of pesticide intermediates and pharmaceutical intermediates. It was listed on the Shenzhen Stock Exchange on September 6, 2011.
Looking for chemical products? Let suppliers reach out to you!
2026-05-16
-
Life Science Ingredients Industry Overview
This issue offers a deep exploration of the evolving pharmaceutical and nutrition landscape, combining data, analysis, and insight to reveal key industry shifts and emerging directions. Support online permanent download.Published in: Nov. 2025
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
The anti-aging genes carried by centenarians can set back the age of the heart by 10 years!
-
Overview of China's API industry in 2023
-
Global Analysis of Active Pharmaceutical Ingredient (API)
-
Professional and technical dry goods: a brief discussion on the selection of starting materials for chemical synthesis APIs
-
Ten billion a year sold, NMN cosmetics raw materials in the end how fire?
-
In 2021, India's Ibuprofen API Export Volume and Price will Fall
-
Corning Cooperative API Plant Puts into Operation
-
API: Industrial Upgrading, Industrial Extension
-
The Continuous Procurement Programme Of 47 National Varieties Has Come
-
The 88th APIChina meet you in Qingdao!
Recommend Reading
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
Moderna to Cut 10 Percent of Staff as COVID Vaccine Sales Plunge Stock Drops 4 Percent
-
BASF Launches Global Expansion Plan for Aroma Ingredients
-
USDA Puts Fresh Money Into Local Food Markets
-
BASF Launches Global Expansion Plan for Aroma Ingredients
-
WACKER’s 2025 Loss Reaches €805 Million as the PACE Cost-Cutting Plan Becomes the Key Variable for 2026
-
Polyethylene Rides High, Price Fluctuations Limited